

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Balance Sheets**  
**September 30, 2021, December 31, 2020, and September 30, 2020**  
**(Expressed in Thousands of New Taiwan Dollars)**  
**(Reviewed, Not Audited)**

<u>Assets</u>			<u>September 30, 2021</u>		<u>December 31, 2020</u>		<u>September 30, 2020</u>	
			<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>
<b>Current assets</b>								
1100	Cash and cash equivalents	6(1)	\$ 981,260	8	\$ 1,034,239	8	\$ 843,581	7
1136	Financial assets at amortized cost - current	8	-	-	400	-	400	-
1150	Notes receivable, net	6(2)	292,023	2	324,175	3	336,557	3
1160	Notes receivable - related parties	7	119,758	1	114,913	1	128,818	1
1170	Accounts receivable, net	6(2)	1,535,206	12	1,671,811	14	1,627,669	13
1180	Accounts receivable - related parties	7	25,892	-	55,237	-	39,626	-
1200	Other receivables	9	36,672	-	85,266	1	33,688	-
1210	Other receivables - related parties	7	185,205	2	188,447	2	187,844	2
1220	Current tax assets		1,857	-	-	-	-	-
130X	Inventories	6(3)	2,356,622	19	2,402,224	19	2,287,363	19
1476	Other financial assets - current	8	12,057	-	-	-	-	-
1479	Other current asset - other		32,731	-	50,639	-	123,558	1
11XX	<b>Total current assets</b>		<u>5,579,283</u>	<u>44</u>	<u>5,927,351</u>	<u>48</u>	<u>5,609,104</u>	<u>46</u>
<b>Non-current assets</b>								
1517	Financial assets at fair value through other comprehensive income - non-current	6(4)	1,249,313	10	741,685	6	794,095	7
1550	Investments accounted for using equity method	6(5)	1,151,017	9	963,485	8	1,012,413	8
1600	Property, plant and equipment	6(6) and 8	4,103,575	32	4,254,179	34	4,204,333	35
1755	Right-of-use assets	6(7)	89,498	1	95,647	1	91,578	1
1760	Investment property	6(6)	58,765	-	-	-	-	-
1780	Intangible assets		18,807	-	27,734	-	17,154	-
1840	Deferred income tax assets		229,358	2	211,744	2	213,146	2
1900	Other non-current assets	6(8) and 9	194,106	2	135,089	1	179,235	1
15XX	<b>Total Non-current assets</b>		<u>7,094,439</u>	<u>56</u>	<u>6,429,563</u>	<u>52</u>	<u>6,511,954</u>	<u>54</u>
1XXX	<b>Total assets</b>		<u>\$ 12,673,722</u>	<u>100</u>	<u>\$ 12,356,914</u>	<u>100</u>	<u>\$ 12,121,058</u>	<u>100</u>

(Continued)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Balance Sheets**  
**September 30, 2021, December 31, 2020, and September 30, 2020**  
**(Expressed in Thousands of New Taiwan Dollars)**  
**(Reviewed, Not Audited)**

<b>Liabilities and Equity</b>			<b>September 30, 2021</b>		<b>December 31, 2020</b>		<b>September 30, 2020</b>	
			<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>
<b>Current liabilities</b>								
2100	Short-term borrowings	6(9) and 8	\$ 878,787	7	\$ 1,143,283	9	\$ 1,391,642	12
2110	Short-term notes and bills payable	6(10)	120,000	1	210,000	2	92,980	1
2130	Contract liabilities - current	6(18)	35,281	-	72,091	-	41,796	-
2150	Notes payable		65,735	1	-	-	-	-
2170	Accounts payable	7	818,210	6	960,728	8	861,076	7
2200	Other payables	6(11)	619,296	5	717,857	6	515,824	4
2230	Current tax liabilities		60,860	1	74,225	1	70,067	1
2280	Lease liabilities - current		14,784	-	13,626	-	11,481	-
2320	Current portion of long-term debt	6(12) and 8	21,000	-	21,000	-	21,000	-
2365	Refund liabilities - current	6(18)	78,352	1	73,512	1	73,480	1
2399	Other current liabilities - other		24,659	-	26,306	-	16,654	-
21XX	<b>Total current liabilities</b>		<u>2,736,964</u>	<u>22</u>	<u>3,312,628</u>	<u>27</u>	<u>3,096,000</u>	<u>26</u>
<b>Non-current liabilities</b>								
2540	Long-term borrowings	6(12) and 8	1,936,000	15	2,046,000	17	2,096,000	17
2570	Deferred income tax liabilities		149,031	1	137,826	1	129,403	1
2580	Lease liabilities - non-current		58,370	1	64,775	-	63,125	1
2600	Other non-current liabilities		153,647	1	168,826	1	165,946	1
25XX	<b>Total non-current liabilities</b>		<u>2,297,048</u>	<u>18</u>	<u>2,417,427</u>	<u>19</u>	<u>2,454,474</u>	<u>20</u>
2XXX	<b>Total liabilities</b>		<u>5,034,012</u>	<u>40</u>	<u>5,730,055</u>	<u>46</u>	<u>5,550,474</u>	<u>46</u>
<b>Equity attributable to owners of parent</b>								
<b>Share capital</b>								
3110	Common stock	6(14)	2,980,811	23	2,980,811	24	2,980,811	25
<b>Capital surplus</b>								
3200	Capital surplus	6(15)	646,000	6	646,000	6	645,774	5
<b>Retained earnings</b>								
3310	Legal reserve	6(16)	610,012	5	535,449	4	535,449	4
3320	Special reserve		188,958	1	188,958	2	188,958	2
3350	Unappropriated retained earnings		2,628,381	21	2,042,582	17	1,947,086	16
<b>Other equity</b>								
3400	Other equity	6(17)	578,062	4	225,931	1	263,791	2
3500	Treasury stock		( 28,054)	-	( 28,054)	-	( 28,054)	-
31XX	<b>Equity attributable to owners of the parent</b>		<u>7,604,170</u>	<u>60</u>	<u>6,591,677</u>	<u>54</u>	<u>6,533,815</u>	<u>54</u>
36XX	<b>Non-controlling interest</b>		<u>35,540</u>	<u>-</u>	<u>35,182</u>	<u>-</u>	<u>36,769</u>	<u>-</u>
3XXX	<b>Total equity</b>		<u>7,639,710</u>	<u>60</u>	<u>6,626,859</u>	<u>54</u>	<u>6,570,584</u>	<u>54</u>
Commitments and contingent liabilities								
3X2X	<b>Total liabilities and equity</b>	6(6),7 and 9	<u>\$ 12,673,722</u>	<u>100</u>	<u>\$ 12,356,914</u>	<u>100</u>	<u>\$ 12,121,058</u>	<u>100</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements of Comprehensive Income**  
**For the Nine Months Ended September 30, 2021 and 2020**  
**(Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)**  
**(Reviewed, Not Audited)**

Item		For the three months ended September 30,				For the nine months ended September 30,				
		2021		2020		2021		2020		
		Amount	%	Amount	%	Amount	%	Amount	%	
4000	Operating revenue	6(18) and 7	\$ 1,909,525	100	\$ 2,018,848	100	\$ 5,938,250	100	\$ 6,017,663	100
5000	Operating costs	6(3)(22)								
		and 7	( 1,229,298)	( 64)	( 1,279,739)	( 63)	( 3,740,149)	( 63)	( 3,793,450)	( 63)
5950	Gross profit		680,227	36	739,109	37	2,198,101	37	2,224,213	37
	Operating Expenses	6(22)								
6100	Selling Expenses		( 456,604)	( 24)	( 468,580)	( 23)	( 1,397,620)	( 24)	( 1,383,754)	( 23)
6200	General and administrative expenses		( 62,948)	( 3)	( 49,980)	( 3)	( 204,505)	( 3)	( 152,123)	( 2)
6300	Research and Development Expenses		( 95,933)	( 5)	( 123,053)	( 6)	( 293,847)	( 5)	( 336,397)	( 6)
6450	Expected credit impairment gains (losses)	12(2)	6,432	-	7,551	-	( 4,700)	-	21,681	-
6000	Total operating expenses		( 609,053)	( 32)	( 634,062)	( 32)	( 1,891,272)	( 32)	( 1,850,593)	( 31)
6900	Operating income		71,174	4	105,047	5	306,829	5	373,620	6
	Non-operating income and expenses									
7100	Interest income	6(19) and 7	3,703	-	2,779	-	12,250	-	9,030	-
7010	Other income	6(20) and 7	48,779	3	30,051	1	60,196	1	59,148	1
7020	Other gains and losses	6(21)	( 1,183)	-	2,704	-	( 10,252)	-	11,059	-
7050	Finance cost	6(23)	( 8,276)	-	( 9,860)	-	( 27,461)	-	( 31,975)	( -)
7060	Share of profit of associates and joint ventures accounted for using equity method	6(5)	46,716	2	16,835	1	129,073	2	126,376	2
7000	Total non-operating income and expenses		89,739	5	42,509	2	163,806	3	173,638	3
7900	<b>Income before income tax</b>		160,913	9	147,556	7	470,635	8	547,258	9
7950	Income tax expense	6(24)	( 31,481)	( 2)	( 29,073)	( 1)	( 107,742)	( 2)	( 82,372)	( 2)
8200	<b>Net income</b>		\$ 129,432	7	\$ 118,483	6	\$ 362,893	6	\$ 464,886	7

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements of Comprehensive Income**  
**For the Nine Months Ended September 30, 2021 and 2020**  
**(Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)**  
**(Reviewed, Not Audited)**

Item	For the three months ended September 30,				For the nine months ended September 30,				
	2021		2020		2021		2020		
	Amount	%	Amount	%	Amount	%	Amount	%	
<b>Other comprehensive income</b>									
<b>Components of other comprehensive income that will not be reclassified to profit or loss</b>									
8316	Unrealized gains from investments in equity instruments measured at fair value through other comprehensive income	6(4)(17)							
		\$ 135,611	7	(\$ 22,677)	( 1)	\$ 965,144	16	\$ 415,898	7
8310	Other comprehensive income that will not be reclassified to profit or loss								
		135,611	7	( 22,677)	( 1)	965,144	16	415,898	7
<b>Components of other comprehensive income that will be reclassified to profit or loss</b>									
8361	Exchange differences on translation of foreign operations								
		( 704)	-	20,726	1	( 20,172)	-	( 12,814)	-
8370	Share of other comprehensive loss of associates and joint ventures accounted for using equity method								
		( 558)	-	( 756)	-	( 967)	-	( 837)	-
8399	Income tax related to items that may be reclassified	6(24)							
		140	-	( 4,145)	-	4,034	-	2,563	-
8360	Other comprehensive loss that will be reclassified to profit or loss								
		( 1,122)	-	15,825	1	( 17,105)	-	( 11,088)	-
8300	<b>Total other comprehensive income for the period</b>								
		\$ 134,489	7	(\$ 6,852)	-	\$ 948,039	16	\$ 404,810	7
8500	<b>Total comprehensive income for the period</b>								
		\$ 263,921	14	\$ 111,631	6	\$ 1,310,932	22	\$ 869,696	14
Net income (loss) attributable to:									
8610	Shareholders of the parent								
		\$ 128,842	7	\$ 117,474	6	\$ 362,535	6	\$ 461,006	7
8620	Non-controlling interests								
		( 590)	-	1,009	-	358	-	3,880	-
		\$ 129,432	7	\$ 118,483	6	\$ 362,893	6	\$ 464,886	7
Total comprehensive income (loss) attributable to:									
8710	Shareholders of the parent								
		\$ 263,331	14	\$ 110,622	6	\$ 1,310,574	22	\$ 865,816	14
8720	Non-controlling interests								
		590	-	1,009	-	358	-	3,880	-
		\$ 263,921	14	\$ 111,631	6	\$ 1,310,932	22	\$ 869,696	14
Earnings per share									
9750	Basic earnings per share								
		\$	0.43		0.39	\$	1.22	\$	1.55
9850	Diluted earnings per share								
		\$	0.43		0.39	\$	1.21	\$	1.54

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statement of Changes in Equity**  
**For the Nine Months Ended September 30, 2021 and 2020**  
**(Expressed in Thousands of New Taiwan Dollars)**  
**(Reviewed, Not Audited)**

	Equity attributable to owners of the parent												Total equity
	Capital surplus				Retained earnings			Other equity interest					
	Share capital - common stock	Additional paid-in capital	Treasury stock transaction	Changes in ownership interests in subsidiaries	Legal reserve	Special reserve	Unappropriated retained earnings	Exchange differences on translation of foreign operations	Unrealized gain (losses) on financial assets measured at fair value through other comprehensive Income	Treasury stock	Total	Non-controlling interest	
<b><u>Nine months ended September 30, 2020</u></b>													
Balance at January 1, 2020	\$ 2,980,811	\$578,416	\$65,765	\$ 1,593	\$496,980	\$188,958	\$ 1,573,890	(\$ 97,944)	\$146,049	(\$ 28,054)	\$ 5,906,464	\$ 32,889	\$5,939,353
Net income	-	-	-	-	-	-	461,006	-	-	-	461,006	3,880	464,886
Other comprehensive income (loss)	6(17)	-	-	-	-	-	-	( 11,088)	415,898	-	404,810	-	404,810
Total comprehensive income (loss)		-	-	-	-	-	461,006	( 11,088)	415,898	-	865,816	3,880	869,696
Appropriations of 2019 earnings	6(16)												
Legal reserve		-	-	-	38,469	-	( 38,469)	-	-	-	-	-	-
Cash dividends		-	-	-	-	-	( 238,465)	-	-	-	( 238,465)	-	( 238,465)
Disposal of equity instruments investments measured at fair value through other comprehensive income	6(4)(17)	-	-	-	-	-	189,124	-	( 189,124)	-	-	-	-
<b>Balance at September 30, 2020</b>	<b>\$ 2,980,811</b>	<b>\$578,416</b>	<b>\$65,765</b>	<b>\$ 1,593</b>	<b>\$535,449</b>	<b>\$188,958</b>	<b>\$1,947,086</b>	<b>(\$109,032)</b>	<b>\$372,823</b>	<b>(\$ 28,054)</b>	<b>\$6,533,815</b>	<b>\$ 36,769</b>	<b>\$6,570,584</b>
<b><u>Nine months ended September 30, 2021</u></b>													
Balance at January 1, 2021	\$ 2,980,811	\$578,416	\$66,240	\$ 1,344	\$535,449	\$188,958	\$2,042,582	(\$ 85,549)	\$311,480	(\$ 28,054)	\$6,591,677	\$ 35,182	\$6,626,859
Net income	-	-	-	-	-	-	362,535	-	-	-	362,535	358	362,893
Other comprehensive income (loss)	6(4)(17)	-	-	-	-	-	-	( 17,105)	965,144	-	948,039	-	948,039
Total comprehensive income (loss)		-	-	-	-	-	362,535	( 17,105)	965,144	-	1,310,574	358	1,310,932
Appropriations of 2020 earnings	6(16)												
Legal reserve		-	-	-	74,563	-	( 74,563)	-	-	-	-	-	-
Cash dividends		-	-	-	-	-	( 298,081)	-	-	-	( 298,081)	-	( 298,081)
Disposal of equity instruments investments measured at fair value through other comprehensive income	6(4)(17)	-	-	-	-	-	595,908	-	( 595,908)	-	-	-	-
<b>Balance at September 30, 2021</b>	<b>\$ 2,980,811</b>	<b>\$578,416</b>	<b>\$66,240</b>	<b>\$ 1,344</b>	<b>\$610,012</b>	<b>\$188,958</b>	<b>\$2,628,381</b>	<b>(\$102,654)</b>	<b>\$680,716</b>	<b>(\$ 28,054)</b>	<b>\$7,604,170</b>	<b>\$ 35,540</b>	<b>\$7,639,710</b>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows**  
**For the Nine Months Ended September 30, 2021 and 2020**  
**(Expressed in Thousands of New Taiwan Dollars)**  
**(Reviewed, Not Audited)**

	<u>For the nine months ended September 30,</u>	
	<u>2021</u>	<u>2020</u>
<u>Cash flows from operating activities</u>		
Income before income tax	\$ 470,635	\$ 547,258
Adjustments		
Adjustments to reconcile profit (loss)		
Depreciation	6(6)(7)(22) 198,216	187,600
Amortization	6(22) 9,849	9,425
Expected credit impairment losses (gains)	12(2) ( 4,700 ) (	21,681 )
Allowance for sales discounts	( 16,505 )	15,300
Interest expense	6(23) 27,461	31,975
Interest income	6(19) ( 12,250 ) (	9,030 )
Dividend income	6(4)(20) ( 5,291 ) (	8,160 )
Net gain of financial assets and liabilities at fair value through profit or loss	6(21) - (	113 )
Share of profit of associates and joint ventures accounted for using equity method	6(5) ( 129,073 ) (	126,376 )
Gain on disposal of property, plant and equipment	6(21) ( 259 ) (	4,832 )
Gains on disposal of investments accounted for using equity method	6(21) - (	738 )
Changes in operating assets and liabilities		
Changes in operating assets		
Proceeds from disposal of financial assets at fair value through profit or loss	-	65,174
Notes Receivable (including related party)	27,307	9,359
Accounts Receivable (including related party)	165,950	32,931
Other Receivable (including related party)	51,836	14,828
Inventories	38,374 (	106,835 )
Other current assets	17,932 (	5,587 )
Changes in operating liabilities		
Contract liabilities	( 36,810 ) (	12,812 )
Notes payable	65,735 (	27,444 )
Accounts payable	( 124,784 ) (	6,620 )
Other payable	( 94,561 ) (	34,300 )
Refund liability	4,840 (	3,919 )
Other current liabilities	( 1,647 ) (	2,030 )
Other non-current liabilities	( 13,679 ) (	22,041 )
Cash inflow generated from operations	638,576	521,332
Interest received	12,250	9,030
Interest paid	( 28,127 ) (	32,660 )
Income tax paid	( 124,614 ) (	59,842 )
Dividend received	77,669	36,128
Net cash flows from operating activities	<u>575,754</u>	<u>473,988</u>

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows**  
**For the Nine Months Ended September 30, 2021 and 2020**  
**(Expressed in Thousands of New Taiwan Dollars)**  
**(Reviewed, Not Audited)**

	<b>For the nine months ended September 30,</b>	
	<b>2021</b>	<b>2020</b>
<b><u>Cash flows from investing activities</u></b>		
Decrease in financing receivable	\$ -	\$ 17,500
Decrease (Increase) in financial assets at amortized cost	400	( 400 )
(Increase) decrease in restricted deposit (listed under other current financial assets)	( 12,057 )	2,974
Acquisition of financial assets at fair value through other comprehensive income 6(4)	( 412,827 )	( 212,021 )
Proceeds from disposal of financial assets at fair value through other comprehensive income 6(4)	861,011	290,688
Proceeds from capital reduction of financial assets at fair value through other comprehensive income 6(4)	9,000	-
Acquisition of investments accounted for using equity method 6(5)	( 131,826 )	-
Proceeds from disposal of subsidiaries investments accounted for using equity method 6(5)	-	22,601
Acquisition of property, plant and equipment 6(26)	( 147,694 )	( 199,488 )
Proceeds from disposal of property, plant and equipment	1,821	4,839
Acquisition of intangible assets	( 51 )	( 6,191 )
(Increase) decrease in refundable deposits	( 27,690 )	1,644
Decrease (Increase) in other non-current assets	5,925	( 8,695 )
Net cash flows (used in) from investing activities	<u>146,012</u>	<u>( 86,549 )</u>
<b><u>Cash flows from financing activities</u></b>		
(Decrease) increase in short-term borrowings	( 264,496 )	111,771
(Decrease) increase in short-term notes and bills payable	( 90,000 )	25,500
Repayment of the principal portion of lease liabilities	( 10,963 )	( 8,141 )
Proceeds from long-term borrowings	300,000	58,000
Repayments of long-term borrowings	( 410,000 )	( 189,000 )
Increase in guarantee deposits received	5,468	2,391
Cash dividends paid 6(16)	( 298,081 )	( 238,465 )
Net cash flows used in financing activities	<u>( 768,072 )</u>	<u>( 237,944 )</u>
Effect of exchange rate changes	( 6,673 )	( 9,754 )
Net increase in cash and cash equivalents	( 52,979 )	139,741
Cash and cash equivalents at beginning of period	<u>1,034,239</u>	<u>703,840</u>
Cash and cash equivalents at end of period	<u>\$ 981,260</u>	<u>\$ 843,581</u>